vs
NPK International Inc.（NPKI）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是NPK International Inc.的1.7倍（$127.1M vs $75.2M），NPK International Inc.同比增速更快（30.7% vs 17.1%），NPK International Inc.自由现金流更多（$5.8M vs $-26.7M），过去两年NPK International Inc.的营收复合增速更高（23.9% vs 20.8%）
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
NPKI vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.7倍
$75.2M
营收增速更快
NPKI
高出13.6%
17.1%
自由现金流更多
NPKI
多$32.5M
$-26.7M
两年增速更快
NPKI
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.2M | $127.1M |
| 净利润 | — | — |
| 毛利率 | 37.7% | 51.0% |
| 营业利润率 | 16.7% | -54.6% |
| 净利率 | — | — |
| 营收同比 | 30.7% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.17 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NPKIZLAB
| Q4 25 | $75.2M | $127.1M | ||
| Q3 25 | $68.8M | $115.4M | ||
| Q2 25 | $68.2M | $109.1M | ||
| Q1 25 | $64.8M | $105.7M | ||
| Q4 24 | $57.5M | $108.5M | ||
| Q3 24 | $44.2M | $101.8M | ||
| Q2 24 | $66.8M | $100.1M | ||
| Q1 24 | $49.0M | $87.1M |
净利润NPKIZLAB
| Q4 25 | — | — | ||
| Q3 25 | $5.7M | $-36.0M | ||
| Q2 25 | $8.7M | $-40.7M | ||
| Q1 25 | $10.0M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-174.3M | $-41.7M | ||
| Q2 24 | $8.0M | $-80.3M | ||
| Q1 24 | $7.3M | $-53.5M |
毛利率NPKIZLAB
| Q4 25 | 37.7% | 51.0% | ||
| Q3 25 | 31.9% | 59.5% | ||
| Q2 25 | 36.9% | 60.6% | ||
| Q1 25 | 39.0% | 63.6% | ||
| Q4 24 | 39.2% | 61.5% | ||
| Q3 24 | 27.5% | 64.1% | ||
| Q2 24 | 37.2% | 64.9% | ||
| Q1 24 | 36.0% | 61.4% |
营业利润率NPKIZLAB
| Q4 25 | 16.7% | -54.6% | ||
| Q3 25 | 13.2% | -42.3% | ||
| Q2 25 | 17.0% | -50.3% | ||
| Q1 25 | 20.9% | -53.3% | ||
| Q4 24 | 20.2% | -62.6% | ||
| Q3 24 | 2.8% | -66.6% | ||
| Q2 24 | 18.7% | -76.0% | ||
| Q1 24 | 14.2% | -80.7% |
净利率NPKIZLAB
| Q4 25 | — | — | ||
| Q3 25 | 8.2% | -31.2% | ||
| Q2 25 | 12.7% | -37.3% | ||
| Q1 25 | 15.4% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -394.3% | -40.9% | ||
| Q2 24 | 12.0% | -80.2% | ||
| Q1 24 | 14.9% | -61.4% |
每股收益（稀释后）NPKIZLAB
| Q4 25 | $0.17 | $-0.05 | ||
| Q3 25 | $0.07 | $-0.03 | ||
| Q2 25 | $0.10 | $-0.04 | ||
| Q1 25 | $0.11 | $-0.04 | ||
| Q4 24 | $0.10 | $-0.09 | ||
| Q3 24 | $-1.99 | $-0.04 | ||
| Q2 24 | $0.09 | $-0.08 | ||
| Q1 24 | $0.08 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.1M | $689.6M |
| 总债务越低越好 | $16.9M | — |
| 股东权益账面价值 | $351.2M | $715.5M |
| 总资产 | $441.8M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.05× | — |
8季度趋势，按日历期对齐
现金及短期投资NPKIZLAB
| Q4 25 | $5.1M | $689.6M | ||
| Q3 25 | $35.6M | $717.2M | ||
| Q2 25 | $26.0M | $732.2M | ||
| Q1 25 | $20.8M | $757.3M | ||
| Q4 24 | $17.8M | $779.7M | ||
| Q3 24 | $42.9M | $616.1M | ||
| Q2 24 | $35.1M | $630.0M | ||
| Q1 24 | $37.7M | $650.8M |
总债务NPKIZLAB
| Q4 25 | $16.9M | — | ||
| Q3 25 | $9.5M | — | ||
| Q2 25 | $9.3M | — | ||
| Q1 25 | $8.1M | — | ||
| Q4 24 | $7.7M | — | ||
| Q3 24 | $14.0M | — | ||
| Q2 24 | $58.0M | — | ||
| Q1 24 | $77.4M | — |
股东权益NPKIZLAB
| Q4 25 | $351.2M | $715.5M | ||
| Q3 25 | $333.9M | $759.9M | ||
| Q2 25 | $328.8M | $791.7M | ||
| Q1 25 | $326.9M | $810.8M | ||
| Q4 24 | $326.5M | $840.9M | ||
| Q3 24 | $316.5M | $667.7M | ||
| Q2 24 | $426.6M | $704.2M | ||
| Q1 24 | $421.6M | $762.2M |
总资产NPKIZLAB
| Q4 25 | $441.8M | $1.2B | ||
| Q3 25 | $404.5M | $1.2B | ||
| Q2 25 | $393.7M | $1.2B | ||
| Q1 25 | $390.0M | $1.2B | ||
| Q4 24 | $393.7M | $1.2B | ||
| Q3 24 | $389.6M | $985.3M | ||
| Q2 24 | $624.8M | $987.4M | ||
| Q1 24 | $640.8M | $988.4M |
负债/权益比NPKIZLAB
| Q4 25 | 0.05× | — | ||
| Q3 25 | 0.03× | — | ||
| Q2 25 | 0.03× | — | ||
| Q1 25 | 0.02× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.18× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.0M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $5.8M | $-26.7M |
| 自由现金流率自由现金流/营收 | 7.6% | -21.0% |
| 资本支出强度资本支出/营收 | 16.3% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $26.3M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流NPKIZLAB
| Q4 25 | $18.0M | $-26.0M | ||
| Q3 25 | $24.7M | $-32.0M | ||
| Q2 25 | $21.4M | $-31.0M | ||
| Q1 25 | $8.8M | $-61.7M | ||
| Q4 24 | $-4.1M | $-55.8M | ||
| Q3 24 | $2.8M | $-26.8M | ||
| Q2 24 | $27.6M | $-42.2M | ||
| Q1 24 | $11.9M | $-90.1M |
自由现金流NPKIZLAB
| Q4 25 | $5.8M | $-26.7M | ||
| Q3 25 | $12.0M | $-35.0M | ||
| Q2 25 | $9.7M | $-33.9M | ||
| Q1 25 | $-1.2M | $-63.2M | ||
| Q4 24 | $-17.7M | $-58.4M | ||
| Q3 24 | $-6.7M | $-28.2M | ||
| Q2 24 | $21.0M | $-42.9M | ||
| Q1 24 | $-1.9M | $-91.1M |
自由现金流率NPKIZLAB
| Q4 25 | 7.6% | -21.0% | ||
| Q3 25 | 17.4% | -30.4% | ||
| Q2 25 | 14.3% | -31.1% | ||
| Q1 25 | -1.8% | -59.9% | ||
| Q4 24 | -30.8% | -53.8% | ||
| Q3 24 | -15.2% | -27.7% | ||
| Q2 24 | 31.4% | -42.9% | ||
| Q1 24 | -3.9% | -104.5% |
资本支出强度NPKIZLAB
| Q4 25 | 16.3% | 0.5% | ||
| Q3 25 | 18.5% | 2.6% | ||
| Q2 25 | 17.1% | 2.6% | ||
| Q1 25 | 15.5% | 1.5% | ||
| Q4 24 | 23.6% | 2.4% | ||
| Q3 24 | 21.4% | 1.3% | ||
| Q2 24 | 9.9% | 0.7% | ||
| Q1 24 | 28.3% | 1.1% |
现金转化率NPKIZLAB
| Q4 25 | — | — | ||
| Q3 25 | 4.37× | — | ||
| Q2 25 | 2.47× | — | ||
| Q1 25 | 0.88× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.43× | — | ||
| Q1 24 | 1.64× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NPKI
| Rental Revenue | $34.8M | 46% |
| Products | $25.5M | 34% |
| Services | $14.9M | 20% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
